November 29th 2024
Your daily dose of the clinical news you may have missed.
November 27th 2024
November 26th 2024
Comments on the draft recommendation can be submitted through December 23, 2024.
November 22nd 2024
At least 1 accurate UTI symptom was found on most of the 331 websites reviewed, but nearly all (80%) included at least 1 inaccurate or misleading one.
November 20th 2024
The recommendations from WikiGuidelines are the first for UTI prevention, diagnosis, and management in over a decade.
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination
Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.
RSV Disease Severity Comparable to Unvaccinated COVID-19, Flu: Daily Dose
GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA
The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.
RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research
In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.
Influenza Vaccine Education in Emergency Departments Improves Uptake, According to New Study
Investigators found vaccine uptake of 41% among unvaccinated individuals who were part of a messaging intervention in the emergency department.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes: Daily Dose
Self-Administered Flu Vaccine May be “Powerful Tool” in Immunization Efforts, Says Expert
Ravi Jhaveri, MD, provides an overview of AstraZeneca's FluMist Quadrivalent vaccine and discusses why it could help increase vaccination rates.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes for up to 1 Year, According to New Data
New research highlights another benefit of COVID-19 vaccination, reported researchers.
Long COVID's Long Road: The Muddled Map at 4 Years
Long COVID affects approximately 20 million people in the US and that number may be conservative. Here, a snapshot, through the fog, of the route they are on.
CDC: Persons with COVID-19, Flu, RSV, Other Respiratory Viruses No Longer Have to Isolate for 5 Days
The updated guidelines reflect the progress made in protecting against severe illness from COVID-19, said CDC Director Mandy Cohen, MD, MPH.
ACIP Recommends Monovalent COVID-19 Booster for Older Adults this Spring
COVID-19 hospitalizations have never fall below 6000/week, according to the ACIP; those aged 65+ have the highest inpatient rate, those aged 75+ have the highest mortality.
First-Ever Long COVID Tissue Bank Launched at University of California San Francisco
"Viral reservoirs" in human tissue may preserve the SARS-CoV-2 virus, provoking an immune response that could drive long COVID-associated symptoms.
COVID-19 Hospitalization Raises Long-Term Mortality Risk Compared to Seasonal Flu: Daily Dose
CDC: One-Third of Children in US Received an HPV Vaccine Dose
According to a new CDC report, 38.6% of children aged 9-17 years received ≥1 doses of the HPV vaccine in 2022.
Young Infants, Children Born Prematurely Face Highest Risk for RSV Hospitalization: Daily Dose
COVID-19 Hospitalization Linked to Higher Long-Term Mortality Risk Compared to Seasonal Influenza, Shows New Research
Hospitalization for COVID-19 was associated with higher long-term risks of death, adverse health outcomes, and significant cumulative excess DALYs vs influenza.
GSK RSV Vaccine Arexvy Under FDA Priority Review for Prevention of RSV in High-Risk Adults Aged 50 to 59 Years
Approval of the application would extend the current Arexvy indication for prevention of RSV in adults aged 60 years and older; a June 2024 PDUFA date is set.
Younger Infants and Children Born Prematurely at Highest Risk for RSV Hospitalization, According to New Study
Results showed nearly one-third of hospitalizations for acute respiratory illness among children aged <5 years were associated with RSV.
CDC: Gonorrhea Cases Declined for First Time in Decade, but Syphilis Keeps Climbing
Reported cases of chlamydia, syphilis, and gonorrhea in the US surpassed 2.5 million for the third time in 5 years, according to CDC.
Updated Monovalent COVID-19 Vaccines Effective Against Symptomatic Infection, Emerging Variants
The updated COVID-19 vaccines were approximately 54% effective against symptomatic SARS-CoV-2 infection, according to new data from the CDC.
FDA Announces Plan for Paxlovid Transition from Emergency Use to Approved Labeling
After March 8, 2024, EUA-labeled Paxlovid will no longer be authorized for use, regardless of expiration date, according to the agency.
Daily Dose: Outpatient C. difficile Underdiagnosed in US
As Measles Outbreak Persists, AAP Urges Clinicians to Ramp Up Infection Control Steps
Measles cases are reported in 6 states, which is not a surprise to one pediatrician who points to the ongoing consequences of falling vaccination rates.
Daily Dose: Vaccination Reduces Risk of Long COVID in Children
Individuals with IBD Hospitalized for COVID-19 at High Risk for Shock, Organ Injury Suggests National Analysis
Among more than 1.5 million persons hospitalized for COVID-19, a history of Crohn disease or ulcerative colitis significantly increased risk for poor outcomes.
New Research Suggests Outpatient C. difficile May be Underdiagnosed in US
Findings showed a high incidence of outpatient Clostridioides difficile infection despite a low rate of testing.
Vaccination Provides Moderate Protection against Long COVID in Children
Vaccination against SARS-CoV-2 was associated with reduced risk of long COVID for at least 12 months in children and adolescents in a new large retrospective study.
Daily Dose: Hospitalization for COVID-19 vs for Flu Linked to More Long-Term Outcomes
Hospitalization for COVID-19 vs for Influenza Linked to More, More Severe Long-Term Outcomes: Study
After hospital discharge, persons who had COVID-19 remained at greater risk of death and myriad adverse health outcomes compared with those who had seasonal flu.
Moderna mRNA RSV Vaccine for Adults Returns Positive Phase 3 Results
Moderna's investigational vaccine against RSV in adults showed mean efficacy of 83% against the infection and is the only mRNA technology-based RSV shot.